MDCX

Medicus Pharma Ltd.

$1.83

-2.92%
SectorHealthcareIndustryDrug Manufacturers - GeneralCountryUnited States

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.

Source: Yahoo Finance
AI summary

Price & performance

1M-76.6%
3M-85.7%
YTD-97.7%
1Y-98.5%
52-week range—
Beta1.10
Full chart and returns against a benchmark

Q-Score

—/ 100

Quality against peers; 50 is the peer median.

Growth—
Risk24
Performance15
Valuation—
Profitability—
Leverage25
Sentiment72
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue—
Net income-$47.3M
Net margin—
Historical fundamentals

Red flags in filings

3active red flags
Going-concern doubtMar 25, 2026
Auditor changeJun 5, 2025
Exchange listing noticeOct 23, 2026
Filings, findings and the timeline

Valuation

MDCXIndustryP/E—38.98P/S—6.74EV/EBITDA—40.57P/B—10.26PEG——
Dividend yield0.00%
Every valuation metric